FDA Okay for Obinutuzumab for Follicular LymphomaFDA Okay for Obinutuzumab for Follicular Lymphoma

The FDA has approved obinutuzumab to be used in combination with bendamustine as second-line treatment for follicular lymphoma. News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Related Links:

Contributors : Romain Guieze ; Catherine J WuSeries Type : Expression profiling by high throughput sequencingOrganism :Resistance to the first approved BCL-2 inhibitor venetoclax is emerging in lymphoid malignancies. The study aimed to identify the genetic determinants of such resistance. From genome-scale screens we determined the genes influencing the sensitivity to BCL-2 inhibition. The present set of data is related to expression changes (assessed by RNA sequencing) observed in the resistant OCI-Ly1 lymphoma cell line as well as those resulting from genetic perturbation (using CRISPR-Cas9) targeting the genes highlight...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Source Type: research
It's the second verdict finding the active ingredient, glyphosate, led to non-Hodgkin's lymphoma in a California man
Source: Health News: CBSNews.com - Category: Consumer Health News Source Type: news
FDA busted two manufacturers of silicone gel-filled breast implants this week for failure to comply with post-approval study requirements. The agency sent warning letters to Irvine, CA-based Mentor Worldwide, a unit of Johnson &Johnson, and to Santa Barbara, CA-based Sientra for deficiencies in each company's post-approval study for silicone breast implant approvals. Breast implants have been a source of contention between patient advocacy groups, industry, and FDA for decades. Implants were banned from the U.S. market from 1992 to 2006, and the devices have been the cause of an over...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
This article reviews the treatment advances in DLBCL with novel and targeted agents that are aimed to improve efficacy especially in those with high-risk features. Expert opinion: Incorporation of novel therapies such as immunomodulatory agents and Bruton tyrosine kinase (BTK) inhibitors in treatment of higher-risk DLBCL subgroups have shown to be effective, however, confirmatory data are required to change the standard of care. While, autologous chimeric antigen receptor (CAR) T-cell therapy targeting CD19-positive B-cells have revolutionized the outcomes of refractory DLBCL, the complexity of its production, post-infusio...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Publication date: 18 March 2019Source: Cancer Cell, Volume 35, Issue 3Author(s): Nicholas F. Kuhn, Terence J. Purdon, Dayenne G. van Leeuwen, Andrea V. Lopez, Kevin J. Curran, Anthony F. Daniyan, Renier J. BrentjensSummaryChimeric antigen receptor (CAR) T cells provide great efficacy in B cell malignancies. However, improved CAR T cell therapies are still needed. Here, we engineered tumor-targeted CAR T cells to constitutively express the immune-stimulatory molecule CD40 ligand (CD40L) and explored efficacy in different mouse leukemia/lymphoma models. We observed that CD40L+ CAR T cells circumvent tumor...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
A federal jury in San Francisco ruled Tuesday that the weedkiller Roundup, a product developed by Monsanto that was acquired by Bayer, played a significant role in a man ’s cancer.  Edwin Hardeman, a California resident, used the weedkiller in his yard, and the jury found that the exposure to Roundup caused him to develop non-Hodgkin lymphoma, according to the Wall Street Journal. Now the case moves into the next phase for jurors to decide whether the Monsanto unit of Bayer is liable, which could…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Edwin Hardeman, 70, of Santa Rosa, California, has non-Hodgkin's lymphoma, a cancer of the immune system after using the weed killer in his garden for 30 years.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Authors: Nagano M, Ayaki T, Koita N, Kitano T, Nishikori M, Goda N, Minamiguchi S, Ikeda A, Takaori-Kondo A, Takahashi R Abstract Primary central nervous system lymphoma (PCNSL) and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) can share clinical features and may be indistinguishable, even after brain biopsy. We encountered a case of Epstein-Barr virus-positive (EBV+) PCNSL recurrence in a patient with clinical features of CLIPPERS, and repeat brain biopsy was required to reach the correct diagnosis. Four years after the initial diagnosis and treatment of P...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
ConclusionLong non-coding RNA MALAT1 sponged miR-195 to regulate proliferation, apoptosis and migration and immune escape abilities of DLBCL by regulation of PD-L1.
Source: Life Sciences - Category: Biology Source Type: research
Condition:   Lymphoma, B-Cell Intervention:   Biological: TAC01-CD19 Sponsor:   Triumvira Immunologics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Hematology | Lymphoma | Treanda